Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients With No Symptoms of the Disease

Completed · Phase 2

Conditions studied: HIV Infections

In brief

To validate that the alteration of codon 215 of reverse transcriptase in plasma virus precedes the increase in viral burden as measured in the peripheral blood and the decline in CD4 count that have been observed in association with clinical failure on zidovudine (AZT). To determine whether alternative regimens of antiretroviral agents alter the course of viral burden as measured in the peripheral blood and CD4 changes in patients with HIV infection. To obtain further data on the safety and immunologic and virologic response to AZT/didanosine/nevirapine. Of the HIV-1 mutations reported to be associated with zidovudine resistance, the mutation at codon 215 of the reverse transcriptase gene is the most commonly occurring and has the greatest impact on susceptibility. When this mutation appears, a change in drugs may prevent further immunologic and virologic deterioration.

Key facts

Study ID

NCT00001045

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

300

Expected to finish

1998-10-01

Last updated by the study team

2021-11-04

Who can join

Age: 13 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Concurrent Medication:
• Allowed:
• Chemoprophylaxis for Pneumocystis carinii pneumonia.
• Antibiotics, antifungals, and antiviral medications, as clinically indicated.
• Regularly prescribed medication such as antipyretics, analgesics, allergy medications, antidepressants, sleep medications, oral contraceptives, or any other medications deemed appropriate by the primary care provider.
• Concurrent Treatment:
• Allowed:
• Limited localized radiation therapy to the skin.
• Prior Medication: Required:
• AZT (minimum 300 mg/day) for at least 1 month (uninterrupted) but no more than 2 years immediately prior to study entry.
• Patients must have:
• Asymptomatic HIV infection.
• CD4 count 300-600 cells/mm3.
• No plasma/serum PCR for codon 215 mutation at screening.
• Prior AZT monotherapy.
• NOTE:
• All Department of Defense (DOD)-eligible patients must be at least 18 years of age. Enrollment of women is encouraged.
• AS PER AMENDMENT 04/03/95:
• DOD female patients must have a negative pregnancy test within 48 hours prior to study entry.

You may not qualify if…

• Co-existing Condition:
• Patients with the following symptoms or conditions are excluded:
• Symptomatic grade 2 or worse peripheral neuropathy.
• Unable to swallow capsules and tablets.
• Other medical condition that contraindicates study participation.
• Concurrent Medication:
• Excluded:
• Systemic cytotoxic chemotherapy.
• Biologic response modifiers (such as interferon, ampligen, or PEG-IL2).
• Anti-HIV agents other than study drugs.
• Other investigational agents.
• Foscarnet unless clinically indicated for unresponsive herpes virus infection.
• Chronic antacid or H-2 blocker use.
• Rifampin or rifamycin class agents.
• Antibiotics containing clavulanic acid.
• Concurrent Treatment:
• Excluded:
• Radiation therapy other than limited localized therapy to skin.
• Patients with the following prior condition are excluded:
• History of pancreatitis.
• Prior Medication:
• Excluded:
• Prior therapy with nucleoside or non-nucleoside antiretroviral agents other than AZT.
• Immune modulating therapies (e.g., IFN-alpha, gp160) within 60 days prior to screening.
• Prior Treatment:

Where it is running

• Stanford at Kaiser / Kaiser Permanente Med Ctr — San Francisco, California, United States
• Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium — San Jose, California, United States
• San Mateo AIDS Program / Stanford Univ — Stanford, California, United States
• Stanford Univ Med Ctr — Stanford, California, United States
• Harbor UCLA Med Ctr — Torrance, California, United States
• Univ of Colorado Health Sciences Ctr — Denver, Colorado, United States
• Georgetown Univ Med Ctr — Washington D.C., District of Columbia, United States
• Children's Hosp of Washington DC — Washington D.C., District of Columbia, United States
• George Washington Univ / Hershey Med Ctr — Washington D.C., District of Columbia, United States
• Walter Reed Army Med Ctr — Washington D.C., District of Columbia, United States
• Emory Univ Hosp / Pediatrics — Atlanta, Georgia, United States
• Emory Hemo Comp Evaluation Clinic / East TN Comp Hemo Ctr — Atlanta, Georgia, United States
• Queens Med Ctr — Honolulu, Hawaii, United States
• Univ of Hawaii — Honolulu, Hawaii, United States
• Indiana Univ Hosp — Indianapolis, Indiana, United States
• Univ of Iowa Hosp and Clinic — Iowa City, Iowa, United States
• State of MD Div of Corrections / Johns Hopkins Univ Hosp — Baltimore, Maryland, United States
• Johns Hopkins Hosp — Baltimore, Maryland, United States
• Natl Naval Med Ctr — Bethesda, Maryland, United States
• Fitzsimmons Army Med Ctr — Rockville, Maryland, United States
• Beth Israel Deaconess Med Ctr — Boston, Massachusetts, United States
• Hennepin County Med Clinic — Minneapolis, Minnesota, United States
• Univ of Minnesota — Minneapolis, Minnesota, United States
• St Paul Ramsey Med Ctr — Saint Paul, Minnesota, United States
• UCLA CARE Ctr — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.